Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Aileron Therapeutics logo

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.75
$3.93
52-Week Range
N/A
Volume
63,385 shs
Average Volume
82,605 shs
Market Capitalization
$45.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

Aileron Therapeutics Rebrands As Rein Therapeutics
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

ALRN Stock Analysis - Frequently Asked Questions

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.20.

Shares of Aileron Therapeutics reverse split on Thursday, November 10th 2022.The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aileron Therapeutics (ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

Last Earnings
8/14/2024
Today
7/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALRN
CIK
1420565
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.73 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-74.08%
Return on Assets
-27.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.30
Quick Ratio
3.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.41 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
21,670,000
Free Float
20,561,000
Market Cap
$45.72 million
Optionable
Not Optionable
Beta
2.24

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ALRN) was last updated on 7/23/2025 by MarketBeat.com Staff
From Our Partners